Salk Polio Vaccine (1955): Field Trial, April 12 Announcement and Cutter Incident
Salk Polio Vaccine (1955): Field Trial, April 12 Announcement and Cutter Incident
How Jonas Salk’s inactivated polio vaccine was tested and licensed in 1955, and why the Cutter manufacturing incident led to stronger safeguards.
Quick answer
How Jonas Salk’s inactivated polio vaccine was tested and licensed in 1955, and why the Cutter manufacturing incident led to stronger safeguards.
Key facts
On this page
Polio before an effective vaccine
Poliomyelitis outbreaks were a major source of fear in mid-century America. Many infections caused no lasting injury, but some led to paralysis, lasting disabilities or death. Children were especially visible among victims, and summer epidemics disrupted schools, recreation and family life.
The National Foundation for Infantile Paralysis, widely associated with the March of Dimes, supported research, patient care and public mobilization. Scientific work toward a vaccine involved numerous researchers and years of virology and clinical investigation.
How Salk’s vaccine worked
Jonas Salk and his colleagues developed a vaccine using poliovirus that had been chemically inactivated so it could stimulate immunity without replicating as live virus. The approach differed from later oral vaccines based on weakened live virus.
The vaccine was not the discovery of one individual working in isolation. Basic virus research, funding, cell-culture advances, manufacturers and thousands of workers made large-scale development possible.
The major field trial
In 1954 an enormous trial assessed vaccine protection and safety. Children across the United States participated in a program organized with the assistance of schools, public-health authorities and volunteers. Thomas Francis Jr. of the University of Michigan directed the independent evaluation.
The trial’s size reflected both the urgency of preventing polio and the need for rigorous evidence before mass immunization. Not every child received the vaccine, and the study employed different evaluation arrangements across locations.
April 12, 1955
On April 12, 1955, Francis announced favorable results and Salk’s vaccine received a U.S. license. The announcement generated extraordinary public excitement, since polio had long caused outbreaks and paralysis.
The date marks a major breakthrough, not the final worldwide eradication of polio. Vaccine production, uptake and public-health systems continued to determine who received protection.
The Cutter Incident
Within weeks, some vaccine produced by Cutter Laboratories contained live poliovirus despite having passed production checks. Vaccinated children and some contacts developed paralytic polio, and deaths occurred. Federal authorities suspended distribution of Cutter’s product and investigated manufacturing and testing failures.
The incident was serious and preventable; it did not establish that correctly manufactured inactivated polio vaccines lacked efficacy. It prompted changes in oversight, testing requirements and quality control.
Later progress
Vaccination sharply reduced polio in the United States over subsequent decades. An oral polio vaccine developed by Albert Sabin later offered another major immunization tool, with different advantages and risks.
The history is one of scientific innovation, public trust, manufacturing responsibility and continuing disease surveillance rather than a single uncomplicated day of triumph.
What the 1955 milestone teaches
The same year illustrates both the power of clinical evidence and the consequences of failed production controls. Understanding both events gives a more accurate account of vaccine history.
The results announcement, licensing and Cutter investigation should be distinguished chronologically so their different meanings remain clear.
Frequently asked questions
When was Salk’s vaccine declared effective?
April 12, 1955.
Was the vaccine a live-virus vaccine?
No. Salk’s vaccine used inactivated poliovirus.
What was the Cutter Incident?
A 1955 manufacturing failure allowed some vaccine batches containing live virus to be distributed.
Sources and further reading
Related history: Employment Act of 1946
